未受严格监管的益生菌市场
本叙述性综述概述了当前益生菌的监管情况,重点关注用于疾病饮食管理(医疗食品)的益生菌。益生菌市场快速增长,但监管因地区而异,除非做出特定疾病相关健康声称,否则益生菌作为食品补充剂监管,重点在于声称的合法性而非功效、安全性和质量。当前监管不足,可能对消费者和医生构成风险,尤其当益生菌用于严重疾病的饮食管理时。
要点
- 益生菌监管因地区而异,除非做出特定疾病相关健康声称,否则作为食品补充剂监管。
- 益生菌许多特性具有菌株特异性,特定配方的安全性和有效性发现不应推广到其他益生菌产品。
- 当前商标法和缺乏严格监管意味着商标所有者可在同一品牌下商业化任何配方,即使与原始产品显著不同。
核心结论
- 当前益生菌监管不足以保护消费者和医生,尤其当益生菌旨在用于严重疾病的饮食管理时。
研究设计与样本
- 本文为叙述性综述,概述当前益生菌监管情况,重点关注用于疾病饮食管理(医疗食品)的益生菌。
主要发现
- 益生菌市场快速增长,既包括旨在增强健康个体健康的食品和补充剂,也包括用于疾病饮食管理的制剂。
- 益生菌监管因地区而异;除非做出特定疾病相关健康声称,否则益生菌作为食品补充剂监管,重点在于任何声称的合法性,而非功效、安全性和质量。
- 益生菌许多特性具有菌株特异性,与特定配方相关的安全性和有效性发现不应推广到其他益生菌产品。
- 制造工艺、条件和成分是产品特性的重要决定因素,若未采取适当措施和控制,制造变更可能导致产品在有效性和安全性上不同于「原始」产品。
- 当前商标法和缺乏严格的益生菌制造监管意味着商标所有者可在同一品牌下商业化任何配方,即使与原始产品显著不同。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: This narrative review provides an overview of the current regulation of probiotics, with a focus on those used for the dietary management of medical conditions (Medical Foods). FINDINGS: The probiotic market has grown rapidly, both for foods and supplements intended to enhance wellness in healthy individuals, and for preparations for the dietary management of disease. Regulation of probiotics varies between regions. Unless they make specific disease-related health claims, probiotics are regulated as food supplements and regulation is focused on the legitimacy of any claims, rather than efficacy, safety and quality. Many properties of probiotics are strain-specific, and safety and efficacy findings associated to specific formulations should not be generalized to other probiotic products. Manufacturing processes, conditions and ingredients are important determinants of product characteristics and changes to manufacturing are likely to give rise to a product not identical to the "original" in efficacy and safety if proper measures and controls are not taken. Current trademark law and the lack of stringent regulation of probiotic manufacturing mean that the trademark owner can commercialize any formulation under the same brand, even if significantly different from the original. These regulatory deficits may have serious consequences for patients where probiotics are used as part of clinical guideline-recommended management of serious conditions such as inflammatory bowel diseases, and may make doctors liable for prescribing a formulation not previously tested for safety and efficacy. CONCLUSIONS: Current regulation of probiotics is inadequate to protect consumers and doctors, especially when probiotics are aimed at the dietary management of serious conditions.
引用
- de Simone C. The Unregulated Probiotic Market. Clin Gastroenterol Hepatol. 2018. PMID: 29378309. doi:10.1016/j.cgh.2018.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。